Literature DB >> 8198988

Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.

F V Cromme1, P F van Bommel, J M Walboomers, M P Gallee, P L Stern, P Kenemans, T J Helmerhorst, M J Stukart, C J Meijer.   

Abstract

In previous studies we have shown down-regulation of class I major histocompatibility complex (MHC) expression in a significant proportion of primary cervical carcinomas, which was found to be strongly correlated with loss of expression of the transporter associated with antigen presentation (TAP). By contrast, class II MHC expression was frequently up-regulated on neoplastic keratinocytes in these malignancies. In order to investigate whether these changes are associated with biological behaviour of the tumours, 20 cervical carcinomas were analyzed for MHC (HLA-A, HLA-B/C, HLA-DR) and TAP-1 expression in the primary tumours and in lymph node metastases by immunohistochemistry. The results showed a significant increase in the prevalence of HLA-A and HLA-B/C down-regulation in metastasised neoplastic cells as compared with the primary tumour (P = 0.01). In all cases this was accompanied by loss of TAP-1 expression. Up-regulated HLA-DR expression was found exclusively in primary tumours and was absent in the corresponding metastases (P = 0.002). These data are consistent with the hypothesis that loss of TAP-1 and the consequent down-regulation of class I MHC expression provides a selective advantage for neoplastic cervical cells during metastasis. Furthermore, the lack of class II MHC expression in metastasised cells either reflects a different local lymphokine production or indicates that these cells may have escaped CD4+ cytotoxic T-lymphocyte (CTL)-mediated killing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198988      PMCID: PMC1969430          DOI: 10.1038/bjc.1994.231

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

Review 1.  Anogenital papillomavirus infection and neoplasia in immunodeficient women.

Authors:  F H Sillman; A Sedlis
Journal:  Obstet Gynecol Clin North Am       Date:  1987-06       Impact factor: 2.844

2.  Class II MHC-bearing keratinocytes induce antigen-specific unresponsiveness in hapten-specific Th1 clones.

Authors:  A A Gaspari; M K Jenkins; S I Katz
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

3.  The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes.

Authors:  P J Snijders; A J van den Brule; H F Schrijnemakers; G Snow; C J Meijer; J M Walboomers
Journal:  J Gen Virol       Date:  1990-01       Impact factor: 3.891

Review 4.  Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers.

Authors:  H zur Hausen
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

5.  Differential expression of HLA class I and II antigens in primary and metastatic melanomas.

Authors:  M A Lopez Nevot; E Garcia; E Pareja; F J Bonal; J Martin; F Ruiz-Cabello; S Serrano; F Garrido
Journal:  J Immunogenet       Date:  1986 Apr-Jun

6.  Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx.

Authors:  F Esteban; A Concha; C Huelin; M Pérez-Ayala; S Pedrinaci; F Ruiz-Cabello; F Garrido
Journal:  Int J Cancer       Date:  1989-03-15       Impact factor: 7.396

7.  Interferon-gamma treatment of B16 melanoma cells: opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread.

Authors:  M Zöller; A Strubel; G Hämmerling; G Andrighetto; A Raz; A Ben-Ze'ev
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

Review 8.  Expression and susceptibility to modulation by interferons of HLA class I and II antigens on melanoma cells. Immunohistochemical analysis and clinical relevance.

Authors:  D J Ruiter; E B Bröcker; S Ferrone
Journal:  J Immunogenet       Date:  1986 Apr-Jun

9.  Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.

Authors:  K Münger; B A Werness; N Dyson; W C Phelps; E Harlow; P M Howley
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

10.  HLA expression in human hepatocellular carcinoma.

Authors:  A C Paterson; R Sciot; M C Kew; F Callea; G M Dusheiko; V J Desmet
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

View more
  26 in total

Review 1.  Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer.

Authors:  Shailender Bhatia; Olga Afanasiev; Paul Nghiem
Journal:  Curr Oncol Rep       Date:  2011-12       Impact factor: 5.075

Review 2.  Functional regulation of immunoproteasomes and transporter associated with antigen processing.

Authors:  L Y Hwang; P T Lieu; P A Peterson; Y Yang
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Role of the HLA System in the Pathogenesis of Dupuytren's Disease.

Authors:  Sara McCarty; Farhatullah Syed; Ardeshir Bayat
Journal:  Hand (N Y)       Date:  2010-02-09

4.  Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.

Authors:  R Khanna; S R Burrows; D J Moss; S L Silins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

5.  Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival.

Authors:  T Tsuchikawa; H Ikeda; Y Cho; M Miyamoto; T Shichinohe; S Hirano; S Kondo
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

6.  NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients.

Authors:  Xiaoyu Li; Fuchun Guo; Yongmei Liu; Hui-Jiao Chen; Feng Wen; Binwen Zou; Dan Li; Qin Qin; Xiaoke Liu; Yali Shen; Yongsheng Wang
Journal:  Oncol Lett       Date:  2015-07-08       Impact factor: 2.967

7.  Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines.

Authors:  H Pandha; A Rigg; J John; N Lemoine
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

8.  Human papillomavirus type 16 (HPV 16) E7 and major histocompatibility complex (MHC) class I and II expression in human keratinocytes in culture.

Authors:  A Hoos; C D'Incan; L Gissmann; A Altmann; F Momburg; I Nindl; W Osen; B H Schönning; I Jochmus
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients.

Authors:  Alfonso Ferrara; Marion Nonn; Peter Sehr; Carola Schreckenberger; Michael Pawlita; Matthias Dürst; Achim Schneider; Andreas M Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-30       Impact factor: 4.553

Review 10.  Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation.

Authors:  R Ehrlich
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.